# A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

> **NCT03525613** · PHASE3 · COMPLETED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 637 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** APL-2
- **DRUG:** APL-2
- **OTHER:** Sham Procedure
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT03525613
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-31
- **Primary completion:** 2021-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525613, "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03525613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*